Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2% ABX 51.91 −0.6% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.45 +0.3% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.395 +2.6% WMS 0.040 +0.0% EMPR 0.830 +1.2%
Production / Operations Routine +

Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date

Optimi Health Manufacturing Milestone Validates Capital Raise But Nasdaq Uplifting Remains Primary Valuation Driver

By The Northwire Desk — AI Analysis May 26, 2026 · 07:01 OPTI · 8.04 Optimi Health Corp.
Executive Summary
  • Optimi Health Corp. announced a production milestone on May 26, 2026, achieving approximately 6% psilocybin content in naturally derived extracts.
  • This represents the highest-purity botanical extract to date for the company's manufacturing platform.
  • The extract is intended to support GMP-grade finished material supply for upcoming clinical research programs in Europe.
  • It also strengthens the existing commercial supply chain for 5 mg psilocybin capsules currently prescribed in Australia under the TGA Authorised Prescriber Scheme.
  • Safety data indicates no serious adverse events reported among patients treated with Optimi's products as of December 2025.
  • The company utilizes a proprietary library of over 200 distinct mushroom genetics for cultivation.
Material Impact
  • Incremental Validation: This news serves as operational validation following the $15 million financing and Nasdaq uplisting completed on May 20, 2026. It confirms management is executing on the use of proceeds to scale production capabilities.
  • No New Revenue Catalyst: Unlike the April 2026 Ibogaine Initiative which opened a new regulatory pathway in the US, this update focuses on existing psilocybin products and European clinical support. It does not introduce a new revenue stream or market entry.
  • Pricing Context: The financing closed at $6.25 USD per share. The stock traded around $7.84 to $8.40 in the days following, suggesting the market viewed the capital raise positively despite dilution. This operational update supports that sentiment but is unlikely to trigger a significant re-rating on its own.
  • Routine Classification: Given the proximity to the major financing event and the nature of the news as an internal manufacturing improvement rather than external regulatory approval or partnership, it falls under Routine - Positive.
OPTI · Price
Company Overview
  • Company: Optimi Health Corp. operates GMP-compliant manufacturing facilities in British Columbia (two 10,000-square-foot sites).
  • Flagship Project: Production of pharmaceutical-grade MDMA and Psilocybin capsules for clinical trials and regulated therapeutic use.
  • Key Markets: Australia (Authorised Prescriber Scheme), Israel (MAPS Clinical Trials), Europe (Clinical Research), Canada (Special Access Program).
  • Regulatory Status: Holds Health Canada Drug Establishment Licence (DEL) with GMP compliance. Obtained FDA Establishment Identifier in 2025.
  • Product Portfolio: 40 mg/60 mg MDMA capsules for PTSD; 5 mg Psilocybin capsules for Treatment-Resistant Depression (TRD).
Read the original news release →

More from Optimi Health Corp.

Jun 29, 2026 · 09:00

Optimi Health Completes Psilocybin Export to Australia for Patients With Treatment-Resistant Depression

Production / Operations Jun 16, 2026 · 08:30

Vertically integrated GMP psychedelic manufacturer scaling clinical supply, but revenue remains negligible and execution is incremental.

Production / Operations Jun 10, 2026 · 09:15

Optimi Health Completes First Export of Psilocybin to the United Kingdom for Phase 2 Clinical Trial

Production / Operations Jun 08, 2026 · 08:00

Psychedelic GMP manufacturer advances ibogaine development amid US policy tailwinds, but commercial revenue remains negligible.

Regulatory Jun 02, 2026 · 07:30

Optimi Health Completes Commercial Psilocybin Production to Address Treatment-Resistant Depression in Australia

Production / Operations May 29, 2026 · 08:30

Australia widens insurance-backed psychedelic therapy access — Optimi’s existing supply chain gains yet another tailwind, but market still awaits proof-of-revenue.

Regulatory